The spread of highly pathogenic avian influenza A (H5N1) viruses in wild birds, its spillover into small mammals in Europe and North America, and the recent case of a teenager in Canada infected with an avian H5N1 virus serve as urgent reminders that the next pandemic could emerge at any time.
The COVID-19 pandemic led to truly remarkable scientific achievements while also exposing critical vulnerabilities in global health systems and the ongoing threat of zoonotic viruses—those that cross species barriers to infect humans. If capable of sustained human-to-human transmission, these viruses can trigger a pandemic. A deeper understanding of the factors that enable interspecies transmission and human-to-human spread is essential for preventing future pandemics and strengthening global resilience to emerging pathogens.
Tackling this challenge is the mission of Université Laval's new Canada Excellence Research Chair (CERC) in Biology and Control of Zoonotic and Pandemic Respiratory Viruses, led by Professor Kanta Subbarao, former Director of the WHO Collaborating Centre for Reference and Research on Influenza at the Peter Doherty Institute for Infection and Immunity in Melbourne.
“The diversity of viruses that infect animal species is vast, making it challenging to prioritize which ones to target for pandemic preparedness, even within specific virus families. A multidisciplinary One Health approach is needed to identify animal viruses with significant pandemic potential and to develop a pipeline for the rapid assessment of antiviral drugs, immunotherapeutics and vaccines.” – Professor Kanta Subbarao
Professor Subbarao is a globally recognized leader in respiratory viruses, with significant contributions to molecular virology and vaccine development for emerging viruses with pandemic potential, including influenza viruses, as well as SARS,MERS and SARS-CoV-2 coronaviruses.
Best known for discovering the PB2 host-range mutation —the most common molecular determinant of avian influenza viruses adaptation to mammals—she also led the characterization of avian influenza viruses that infect humans, including the H5N1 virus in Hong Kong in 1997. As Principal Investigator of a CRADA with MedImmune, she spearheaded a bench-to-bedside program to develop and evaluate pandemic influenza vaccines. VIDÉO CERC
Now leading the CERC, which seeks to mitigate the impact of future respiratory virus pandemics, Dr. Subbarao will assemble a multidisciplinary team to strengthen our ability to anticipate, prepare for, and respond to potential pandemic threats. The team will collaborate with veterinarians and ecologists to study the animal-human interface, while also working with experts in science, medicine, engineering, and pharmacy—across academia and industry—on immunity, as well as drug and vaccine development and evaluation.
This interdisciplinary research approach, supported by Université Laval’s cutting-edge infrastructure, will drive advancements in biology and public health, train the next generation of researchers, foster strong collaborations with academia and industry, and influence policy at the national and global levels.